openPR Logo
Press release

Precise Analysis on Global Atrial Fibrillation Clinical Trials Reviewed for H1, 2017

06-21-2017 02:31 PM CET | Health & Medicine

Press release from: Pharmaceutical Research Reports [MRH]

Pharmaceutical Industry Research Reports - MRH

Pharmaceutical Industry Research Reports - MRH

Rapid increase in the geriatric population across the world, coupled with the rising prevalence of various disorders such as obesity and hypertension, as a result, is pushing the global atrial fibrillation market significantly. In recent years, the favorable results of clinical trials of drugs and therapies intended for the treatment of atrial fibrillation have supported the growth of this market. A fresh review analysis on the ongoing clinical trials has been presented in a study titled as “Atrial Fibrillation Global Clinical Trials Review, H1, 2017”, which has been added to the mega-repository of Market Research Hub (MRH).

Request Free Sample Report:

The report identifies that there are numerous ongoing clinical trials on atrial fibrillation (AF) currently taking place, which are aiming to improve the treatment of the disease condition. This 150-pages research study provides a snapshot of the global clinical trials landscape and offers top-level data related to the clinical trials by covering some major regions, country (G7 & E7), trial phase, trial status, sponsor type and end point status. Moreover, enrollment trends for the past five years and latest news & press releases regarding these clinical trials for the past three months are outlined.
Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. Each year millions of Americans are diagnosed and treated for this condition. Although up to 90% of AF episodes may not cause symptoms, many patients experience a wide variety of symptoms, including palpitations, dyspnea, fatigue, dizziness, angina, and decompensated heart failure. It has been estimated that atrial rhythm changes occur in about 4% of the population and it affects approximately 2.2 million people, in the U.S.

Make An Enquiry:

The study further includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The precise analysis of clinical trials is collated from 80+ different clinical trial registries, conferences, journals, news etc. The treatment goals of atrial fibrillation (AF or AFib) start with a proper diagnosis through an in-depth examination from a physician. Currently, one of the most widely used treatments is catheter ablation that involves radiofrequency energy or freezing directed through a catheter to specific heart cells.

Moving further, the report reviews top companies involved and enlists all their active and ongoing trials (Trial title, Phase, and Status) pertaining to the company. Atrial fibrillation therapeutics clinical trials, in the global market, together with ongoing clinical trials by prominent drugs are also highlighted. By the above information, the report enhances the decision-making capabilities and helps market players to create some effective counter-strategies to gain competitive advantage.

Browse Full Report With TOC:

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Read Industry News At:

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Precise Analysis on Global Atrial Fibrillation Clinical Trials Reviewed for H1, 2017 here

News-ID: 589136 • Views: 143

More Releases from Pharmaceutical Research Reports [MRH]

Pipeline Analysis on Phenylalanine 4 Hydroxylase Reviewed by Company, Profiled D …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC - Pipeline Review, H1 2017”. This research study outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopepti …
According to the latest pipeline analysis, Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. To elaborate further details on its global demand, a study titled “Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein
Global Indoleamine 2, 3 Dioxygenase 1 Industry Vital Pipeline Review for the Fir …
The indoleamine 2, 3 Dioxygenase 1 or IDO1 market is developing since the cancer treatment sector relies heavily on its’ in-depth research and high-quality treatments. Looking into this huge potential, a new study has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Indoleamine 2, 3 Dioxygenase 1 (Indoleamine Pyrrole 2, 3 Dioxygenase 1 or IDO1 or EC - Pipeline Review, H1 2017‘’.
Prosthetic Joint Infections - Clinical Trials Rise Due to Higher Disease Inciden …
Market Research HUB's Pharmaceutical and Healthcare latest pipeline guide Prosthetic joint infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news

All 5 Releases

More Releases for MRH

Global Dystrophin Pharmaceuticals Industry Research Report - MRH
A fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “Global Dystrophin Market Research Report” which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview. The report anticipates that the sector for Pharmaceutical would rise at a positive CAGR during the period 2017-2022. Request For Free Sample -
Global VOD In Hospitality Industry Trends and Forecast Report- MRH Report (2017) …
MRH announced a 'Medical Equipment' related topic "VOD In Hospitality Report by Material, Application, and Geography-Global Forecast to 2021" is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe, and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Request For Free Sample Report: The report firstly introduced the VOD In Hospitality basics:
Global Neuromodulation Market Research Report 2016 - MRH
This report of MRH studies Neuromodulation in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacture. Request Free Sample Report: Area Covering Medtronic, Inc. (U.S.) Boston Scientific Corporation (U.S.) St. Jude Medical, Inc. (U.S.) Synapse Biomedical, Inc. (U.S.) Nevro Corporation (U.S.) Neurosigma, Inc. (U.S.) Neuropace, Inc. (U.S.). Neuronetics, Inc. (U.S.) Cyberonics, Inc. (U.S.) BioControl Medical (Israel) Market Segment by Regions,
Smokeless Tobacco in Germany, 2017 Report : MRH
Although Germany is the largest market for cigarettes in Western Europe it has one of the smallest smokeless tobacco markets. Smokeless tobacco currently accounts for only 1.2% of the whole tobacco market as consumers prefer traditional cigarettes and cigars. Nevertheless, the market is well established in Germany due to its proximity to Scandavian countries to the north but is not popular among young adults. In addition to this, new EU
Global Beef Market Research Report 2017 - MRH
MRH Report: The "Global Beef Market" Research Report 2017 is a professional and in-depth study on the current state of the Beef market. Annual estimates and forecasts are provided for the period 2016 through 2021. Also, a six-year historic analysis is provided for these markets. The global market for Beef is expected to reach about 232243 Million USD by 2021 from 237639 Million USD in 2016, registering a Compounded Annual
Global Billiards and Snooker Equipment Market Research Report 2017 - MRH
Market Research Hub announced the report on the retailing topic "Billiards and Snooker Equipment Market Research". Request a Free Sample Report: Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Billiards and Snooker Equipment in these regions, from 2012 to 2022 (forecast), covering North America Europe China Japan Southeast Asia India Global Billiards and Snooker Equipment market competition by top manufacturers, with production, price, revenue (value)